Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to 0.14.

  • Serina Therapeutics' Equity Ratio rose 10762.36% to 0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14, marking a year-over-year increase of 10762.36%. This contributed to the annual value of 0.1 for FY2024, which is 10264.73% up from last year.
  • Serina Therapeutics' Equity Ratio amounted to 0.14 in Q3 2025, which was up 10762.36% from 0.2 recorded in Q2 2025.
  • Serina Therapeutics' Equity Ratio's 5-year high stood at 0.25 during Q1 2025, with a 5-year trough of 7.54 in Q3 2022.
  • Over the past 5 years, Serina Therapeutics' median Equity Ratio value was 1.93 (recorded in 2021), while the average stood at 2.51.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 123076.15% in 2021, then skyrocketed by 16366.75% in 2025.
  • Quarter analysis of 5 years shows Serina Therapeutics' Equity Ratio stood at 3.77 in 2021, then tumbled by 41.9% to 5.34 in 2022, then soared by 32.6% to 3.6 in 2023, then soared by 102.65% to 0.1 in 2024, then soared by 48.73% to 0.14 in 2025.
  • Its Equity Ratio was 0.14 in Q3 2025, compared to 0.2 in Q2 2025 and 0.25 in Q1 2025.